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Abstract
Previously we identified palmitoyl-, oleoyl-, linoleoyl-, and arachidonoyl-lysophosphatidylcholine (LPC 16:0, 18:1, 18:2 and
20:4) as the most prominent LPC species generated by endothelial lipase (EL). In the present study, we examined the impact
of those LPC on acetylcholine (ACh)- induced vascular relaxation. All tested LPC attenuated ACh-induced relaxation,
measured ex vivo, using mouse aortic rings and wire myography. The rank order of potency was as follows:
18:2.20:4.16:0.18:1. The attenuating effect of LPC 16:0 on relaxation was augmented by indomethacin-mediated
cyclooxygenase (COX)-inhibition and CAY10441, a prostacyclin (PGI2)- receptor (IP) antagonist. Relaxation attenuated by LPC
20:4 and 18:2 was improved by indomethacin and SQ29548, a thromboxane A2 (TXA2)- receptor antagonist. The effect of
LPC 20:4 could also be improved by TXA2- and PGI2-synthase inhibitors. As determined by EIA assays, the tested LPC
promoted secretion of PGI2, TXA2, PGF2a, and PGE2, however, with markedly different potencies. LPC 16:0 was the most
potent inducer of superoxide anion production by mouse aortic rings, followed by LPC 18:2, 20:4 and 18:1, respectively. The
strong antioxidant tempol recovered relaxation impairment caused by LPC 18:2, 18:1 and 20:4, but not by LPC 16:0. The
tested LPC attenuate ACh-induced relaxation through induction of proconstricting prostanoids and superoxide anions. The
potency of attenuating relaxation and the relative contribution of underlying mechanisms are strongly related to LPC acyl-
chain length and degree of saturation.
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Introduction
Lysophosphatidylcholines (LPC) are bioactive phospholipids
generated by various biological processes including: i) phospholi-
pase A2 (PLA2)-catalysed cleavage of plasma membrane and
lipoprotein phosphatidylcholine (PC) [1], ii) lecithin cholesterol
acyltransferase (LCAT) activity in high density lipoproteins (HDL)
[2], and iii) oxidation of low density lipoproteins (LDL) [3]. In
contrast to exclusively saturated LPC species generated by
aforementioned processes, both hepatic lipase (HL) and endothe-
lial lipase (EL) generate in addition to LPC 16:0 unsaturated
species 18:1, 18:2 and 20:4 by cleaving HDL-PC [4,5].
Under physiological conditions the plasma concentration of
LPC is around 100–170 mM [6], with elevations under patho-
physiological conditions up to millimolar concentrations in e.g.
hyperlipidemic subjects [7]. LPC in plasma are distributed
between albumin and other carrier proteins as well as lipoproteins
[8,9]. Free LPC might occur locally during an excessive lipolysis
and concomitant saturation of carrier proteins with lipolysis
products. The interaction of free LPC with vascular endothelium,
as found for LPC 16:0, results in altered endothelial function and
impaired vascular reactivity [10,11].
The maintenance of normal vascular tone is largely dependent
on the capability of vascular endothelium to maintain the fine
balance between endothelium-derived relaxing factors (EDRF)
and endothelium-derived contracting factors (EDCF). Upon
stimulation with various agonists EDRF and EDCF released from
vascular endothelial cells diffuse to underlying smooth muscle cells,
where they act on specific receptors and cause relaxation or
contraction [12]. While nitric oxide (NO) and endothelium-
derived hyperpolarizing factor (EDHF) are principal EDRF,
prostanoids, the products of cyclooxygenase (COX)-1 and -2,
may act as both EDRF and EDCF [12,13].
Endothelium-derived PGI2 promotes relaxation of underlying
vascular smooth muscle cells through activation of PGI2- (IP)
receptors [13]. However, under certain conditions, PGI2, like
TXA2, causes contraction through activation of TXA2- (TP)
receptors [14]. PGE2 promotes relaxation via PGE2- (EP)
receptors subtypes EP2 and EP4, whereas by acting via EP1, EP3
and TP receptors it causes constriction [15,16]. Likewise, PGF2a
and isoprostanes, cause contraction through activation of TP
receptors on vascular smooth muscle cells [17,18]. Additionally,
endothelium-derived ROS may act as potent EDCF either directly
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by promoting depolarization of vascular smooth muscle [19] or
indirectly by reducing NO bioavailability [20].
Previously we found that the capacity and underlying mecha-
nisms of palmitoyl-LPC (16:0 LPC), oleoyl-LPC (18:1 LPC),
linoleoyl-LPC (18:2 LPC) and arachidonoyl-LPC (20:4 LPC) to
modulate endothelial prostanoid production were remarkably
different and related to the acyl-chain length as well as degree of
saturation [21]. At present only the impact of 16:0 LPC on
vascular reactivity has been investigated.
Here we tested the hypothesis of acyl chain dependency of LPC
in altering vascular reactivity. To this end we compared the effects
of LPC 18:1, 18:2 and 20:4 with LPC 16:0 on ACh-induced
vasorelaxation in an ex vivo system using mouse aortic rings and
myography. We found that the tested LPC attenuate ACh-induced
relaxation through induction of proconstricting prostanoids and
superoxide anions whereby the potency of attenuating relaxation
and the relative contribution of underlying mechanisms are
strongly related to LPC acyl-chain length and degree of saturation.
Materials and Methods
LPC
LPC 16:0, 18:1, 18:2 and 20:4 were purchased from Avanti
Polar Lipids, Alabaster, AL or prepared as described [6]. LPC
were dissolved in chloroform/methanol and stored at 220uC
under argon atmosphere. Required amounts of LPC were dried
under a stream of nitrogen or argon and re-dissolved in PBS
(pH 7.4) before the experiment.
Mice and tissue preparation
Mice received care in accordance with the Austrian law on
experimentation with laboratory animals, which is based on the
U.S. National Institutes of Health guidelines. Male C57BL/6 mice
(10–12 weeks old) provided by Himberg, Austria, were killed by
cervical dislocation. The descending thoracic aorta was isolated
and dissected free of adherent tissue.
Organ Chamber Experiments
Aortic rings approximately 2 mm in length were cut from
descending thoracic aorta. The arterial rings were positioned in
small wire myograph chambers (Danish MyoTechnology, Aarhus,
Denmark), which contained physiological salt solution (PSS)
(114 mM NaCl, 4.7 mM KCl, 0.8 mM KH2PO4, 1.2 mM
MgCl2, 2.5 mM CaCl2, 25 mM NaHCO3 and 11 mM D-glucose
pH 7.4) aerated with 5% CO2/95% O2 at 37uC. The myograph
chambers were connected to force transducers for isometric
tension recording (PowerLab, ADInstruments). The rings were
heated in PSS buffer to 37uC. An initial preload of 10 mN was
applied, and the rings were allowed to stabilize for 30 min. PSS
containing 60 mM KCl was used to determine maximum
contractility of the tissue. When the developed tension attained
its peak value, the rings were relaxed by rinsing with the buffer.
Next, the rings were pre-contracted with increasing concentrations
of norepinephrine (NE) (1 nM–0.3 mM) (Sigma-Aldrich) to pro-
duce 80% of the maximum contraction achieved by 60 mM KCl,
followed by endothelium-dependent relaxation to cumulatively
increasing concentrations of acetylcholine chloride (ACh) (1 nM–
0.3 mM) (Sigma-Aldrich). After washout and equilibration, the
rings were preincubated with 10 mM LPC in the presence or
absence of inhibitors for 30 minutes, followed by contraction (NE)
– relaxation (ACh) cycle as described above. Relaxation values
were expressed as a percentage of the NE-induced contraction.
The endothelium-independent relaxation was examined by
exposure of rings to increasing concentrations (0.1 nM to
30 nM) of sodium nitroprusside (SNP) (Sigma-Aldrich), a nitric
oxide (NO)-donor.
Pharmacological inhibitors
Indomethacin (non-selective COX inhibitor; 20 mM), N5-
[imino(nitroamino)methyl]-L-ornithine (L-NNA; eNOS inhibitor;
200 mM), Tempol (superoxide dismutase (SOD)- mimetic;
200 mM), SQ29548 (TXA2 receptor antagonist; 10 mM), Diethyl-
dithiocarbamic acid diethylammonium salt (DETCA) (SOD
inhibitor; 10 mM) and TIRON (superoxide ion scavenger;
100 mM) were from Sigma (Saint Louis, MO). Tranylcypromine
(PGI2 synthase inhibitor; 10 mM) was from Calbiochem. Fure-
grelate (TXA2 synthase inhibitor; 10 mM) and CAY10441 (IP
receptor antagonist; 1 mM) were from Cayman Chemicals (Ann
Arbor, Michigan, USA). Stock solutions (10 mM) of Indomethacin
and Tranylcypromine were made in dimethylsulfoxide (DMSO)
and further diluted with distilled water. The stock solution
(10 mM) of SQ29548 was prepared in ethanol and further diluted
with distilled water. All other drugs were dissolved in distilled
water.
Prostanoid measurement
Mouse aortic rings (approximately 2-mm in length) were
incubated in 200 ml aerated PSS under cell culture conditions at
37uC for 1 h. Thereafter, buffer was replaced with fresh PSS
supplemented with PSS (control) or LPC (10 mM) followed by
further incubation under cell culture conditions at 37uC for 1 h.
The buffers were flash frozen in liquid nitrogen for subsequent
prostanoid quantification and rings were homogenized for protein
quantification. Protein concentration was determined with the
BCA protein assay kit (Novagen, Darmstadt, Germany). The
concentrations of 6-Keto-PGF1a, TXB2, PGE2 and PGF2a were
measured by corresponding correlate-EIA kits (Cayman, Ann
Arbor, MI) according to the manufacturer’s protocol.
Superoxide anions measurement
Superoxide anions were measured as described [22] with some
modifications. Mouse aortic rings were equilibrated in 100 ml PSS
buffer containing 10 mM DETCA, an SOD-inhibitor and 10 mM
lucigenin (Sigma) at 37uC for 30 minutes. LPC (10 mM) was added
to the tubes immediately before measurements. The luminometer
(Lumat LB9501, Berthold technologies, Germany) was set up to
report arbitrary units of emitted light (RLU). Measurements were
taken in triplicates every 10 seconds. In addition, blank measure-
ments with and without aortic rings were collected in the same way
to subtract background emission. The amounts of released
superoxide anions (chemiluminiscence units) were normalised to
protein content of respective aortic rings. The RLU obtained in
control incubations with PSS were set to 100% and the RLU
obtained by LPC’s were expressed as percentage of the control
Nitrite determination
Nitrite as an indicator of NO production was determined
according to a previously described fluorometric HPLC method
[23] utilizing the reaction of nitrite with 2,3-diaminonaphthalene
(DAN). In brief, the nitrite levels were determined in the
myography incubation buffers. Samples (500 ml) were taken and
snap frozen in liquid nitrogen. After thawing 100 mL of the sample
(incubation buffer) was incubated at 24uC with 10 mL of
316 mmol/L DAN (in 0.62 mol/L HCl) for 10 min, followed by
addition of 10 mL of 2.8 mol/L NaOH. This reaction mixture was
directly used for chromatographic separation (injection volume:
20 mL) of the formed 2, 3-naphthotriazole (NAT). Nitrite
Lysophosphatidylcholine and Vasorelaxation
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standards (range: 0–2 mmol/L) were derivatized accordingly. NAT
was isocratically separated on a 5-mm ODS hypersil column
(15064.6 mm) guarded by a 5-mm ODS hypersil column
(1064.6 mm; Uniguard holder) with a 30 mmol/L sodium
phosphate buffer (pH 7.5) containing 50% methanol (flow rate:
0.8 mL/min). Fluorescence was monitored at an excitation
wavelength of 375 nm and an emission wavelength of 415 nm.
The HPLC apparatus consisted of an L-2200 autosampler, L-2130
HTA pump and L-2480 fluorescence detector (VWR Hitachi,
Tokyo, Japan). Detector signals were recorded with a personal
computer. The EZchrom Elite (Scientific Software Inc., San
Ramon, CA USA) was used for data requisition and analysis. The
detection limit for nitrite was 10 pmol/mL.
Statistical Analysis
EC50 values (the ACh concentrations required to achieve 50%
of maximal relaxation) are expressed as mean with 95%
confidence intervals. Data are otherwise expressed as mean 6
SEM. The significance of the difference between group means was
analyzed by two-way analysis of variance and the Bonferroni-post
test for samples. For prostanoid, nitrite and ROS measurements
control and LPC treated aortic rings were compared by student’s
T-test. Values of P,0.05 (*), P,0.01 (**), and P,0.001 (***) were
taken as statistically significant. Statistical analysis was performed
by Prism Version 4.0 (GraphPad Software, USA).
Results
LPC attenuate ACh-induced endothelium-dependent
relaxation
All tested LPC attenuated aortic ring relaxation to cumulatively
increasing concentrations of ACh with rank order of potency as
follows: 18:2.20:4.16:0.18:1 (Fig. 1). EC50 values for LPC
18:2, 20:4, 16:0 and 18:1 were 354 nM (261–479), 298 nM (222–
401), 214 nM (143–314) and 115 nM (86.2–155), respectively.
The subsequent relaxation of the same rings to SNP, following
precontraction with NE, was not affected by either of the tested
LPC (Fig. S1), indicating that responsiveness of aortic smooth
muscle layers to NO was not impaired by prior exposure to LPC.
Figure 1. ACh-induced relaxation of mouse aortic rings is attenuated by LPC. The rings were preincubated without (no LPC) or with 10 mM
LPC 16:0 (A), 18:1 (B), 18:2 (C) or 20:4 (D) for 30 minutes, followed by precontraction with NE and cumulative addition of ACh. Relaxation values were
expressed as a percentage of the NE-induced contraction. Results of each experimental condition are mean 6 SEM of 24 rings for each case from 6
mice. *P,0.05, **P,0.01***P,0.001.
doi:10.1371/journal.pone.0065155.g001
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The role of COX and PGI2 in LPC- mediated attenuation
of vascular relaxation
To examine whether COX-derived vasoconstricting prosta-
noids are responsible for the observed LPC-induced attenuation of
relaxation, myography experiments were performed in the
absence or presence of the non-selective COX inhibitor,
indomethacin. In contrast to our expectation, indomethacin
augmented the attenuating effect of LPC 16:0 on ACh-induced
relaxation (Fig. 2A). Similar finding was obtained with CAY10441,
an IP receptor antagonist (Fig. 2B). In contrast, indomethacin
improved the relaxation attenuated by LPC 18:2 (Fig. 2C) and
20:4 (Fig. 2D), but had no effect on the attenuation caused by LPC
18:1 (Fig. S2).
TP receptors are involved in LPC 18:2- and 20:4-
mediated attenuation of vascular relaxation
Considering the well-established importance of TP receptors in
mediating endothelium-dependent contractions [24,25], we ex-
amined whether SQ29548, a TP receptor antagonist could
attenuate the inhibitory effect of LPC on vasorelaxation.
SQ29548 markedly attenuated the inhibitory effect of LPC 18:2
(Fig. 3A) and significantly improved relaxation attenuated with
LPC 20:4 (Fig. 3B), but had no significant impact on relaxation
attenuated with LPC 16:0 or 18:1, respectively (not shown).
The role of TXA2 and PGI2 in LPC 18:2- and 20:4-
mediated attenuation of vascular relaxation
Since TP receptors can be activated by both TXA2 and PGI2
[17], we tested the involvement of both prostanoids in LPC 18:2-
and 20:4-induced attenuation of relaxation. Attenuated relaxation
observed in the presence of LPC 20:4 was markedly improved
upon inhibition of TXA2-synthase by furegrelate (Fig. 4A) as well
as upon inhibition of PGI2-synthase by tranylcypromine (Fig. 4B).
The co-application of both inhibitors resulted in further improve-
ment of relaxation, however without complete restoration of
relaxation, suggesting the involvement of additional 20:4 LPC-
induced vasoconstricting factors. Neither of both inhibitors could
recover relaxation impaired by LPC 18:2 (Fig. S3A, S3B).
Figure 2. Impact of COX-inhibition and prostacyclin-action on LPC-induced attenuation of relaxation. The rings were preincubated
without (no LPC) or with 10 mM of indicated LPC in the absence or presence of (A,C,D) indomethacin, a non-selective COX inhibitor (20 mM) or (B)
CAY10441, a IP receptor antagonist (1 mM) for 30 minutes, followed by precontraction with NE and cumulative addition of ACh. Relaxation values
were expressed as a percentage of the NE-induced contraction. Indomethacin improved relaxation attenuated by LPC 18:2 (C) and 20:4 (D).
Relaxation attenuated by LPC 16:0 was exaggerated by indomethacin and CAY10441. Results are mean6 SEM of 20 rings for each case from 10 mice
(A), 8 rings for each case from 3 mice (B) and 12 rings for each case from 6 mice (C,D).
doi:10.1371/journal.pone.0065155.g002
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Prostanoid release from LPC-treated aortic rings
To examine whether the production of prostanoids implicated
in LPC-induced attenuation of relaxation (Figs. 1–4) was increased
by LPC, we measured concentrations of prostanoids produced and
secreted by aortic rings upon incubation with LPC. Compared
with PSS-treated control incubations, LPC 20:4 was the most
potent inducer of PGI2 production (measured as 6-Keto PGF1a, a
stable degradation product of PGI2), followed by 18:2 and 16:0
(Fig. 5A). The effect of LPC 18:1 concerning prostanoids did not
reach statistical significance (Fig. 5A). The release of TXB2 was
significantly increased only with LPC 20:4 (Fig. 5B). While PGE2
production was significantly increased only upon incubation with
LPC 20:4 (Fig. 5C), the levels of PGF2a were significantly
increased with LPC 20:4 and 18:2, respectively (Fig. 5D).
LPC-induced oxidative stress contributes to LPC-induced
attenuation of vascular relaxation
Since superoxide anions are established EDCF [17], we
examined whether their production is triggered by LPC and
whether they contribute to the observed LPC-induced impairment
of relaxation. As shown in Figure 6A all LPC induced superoxide
anion production in mouse aortic rings with the following order of
potency: 16:0.18:2.20:4.18:1. The SOD mimetic tempol [26]
improved relaxation impairment caused by LPC 18:1 (Fig. 6C),
18:2 (Fig. 6D) and 20:4 (Fig. 6E) but not that caused by LPC 16:0
(Fig. 6B).
Discussion
The present study investigated the effect of LPC 16:0, 18:1,18:2
and 20:4, the most prominent LPC in human plasma [6], on
endothelium-dependent relaxation in response to ACh. Previously,
we identified these LPC as major hydrolysis products generated by
the action of EL on HDL [4]. Considering the very high plasma
levels under pathophysiological conditions (e.g. hyperlipidemic
subjects) and their production by EL on the surface of vascular
endothelial cells, these LPC might have a pronounced effect on
endothelial function and vascular reactivity. Numerous studies
have examined the effect of LPC on vascular reactivity. However,
in these studies exclusively LPC 16:0 was used as a model LPC. To
the best of our knowledge the present study is the first one to
address the effect of unsaturated LPC 18:1, 18:2 and 20:4 on ACh-
induced relaxation and to compare the effect with the saturated
LPC 16:0.
We found that all LPC caused a pronounced attenuation of
endothelium-dependent relaxation (EDR) to ACh with remarkable
acyl-chain dependent differences regarding the potency and
underlying mechanisms. LPC did not alter the SNP-induced
relaxation (Fig. S1). This demonstrates that LPC are not toxic to
smooth muscle cells and that the observed LPC-mediated
attenuation of relaxation is an endothelium-dependent effect.
Neither of the tested LPC modified the contractile response to NE,
nor did they induce contraction when co-applied with the eNOS
inhibitor L-NNA (not shown).
L-NNA completely inhibited, whereas indomethacin had no
effect on ACh-induced relaxation of mouse aortic rings (Fig. S4A,
S4B). Thus, NO seems to be the major mediator of ACh-induced
relaxation in our experimental model. This is in line with the
inability of ACh to alter vascular tone in aortic rings from eNOS
deficient mice [27]. Accordingly, the observed attenuation of
relaxation caused by LPC may reflect increased production and
activity of EDCF, with concomitant counteraction of ACh-
induced NO-mediated relaxation. This is similar to the inability
of endothelial NO to curtail the effect of EDCF observed in
arteries of aging and diseased (essential hypertension, diabetes)
animals and humans [28–30]. In spontaneous hypertensive rats
(SHR) and in essential hypertensive patients, impaired vasodila-
tation was almost normalized by the COX-inhibitor indometha-
cin, indicating that COX-derived vasoconstrictors are key EDCF
responsible for impaired endothelial function and blunted
vasorelaxation [30].
Improvement of relaxation attenuated by LPC 18:2 and 20:4
upon inhibition of both COX (Fig. 2C, 2D) and TP receptors
(Fig. 3A, 3B), indicated the involvement of COX-derived EDCF,
which are capable of inducing contraction by acting via TP
receptors [17,30]. These receptors are highly expressed in mouse
aortic smooth muscle cells [31]. Both PGI2 and TXA2 were
markedly induced by LPC 20:4 (Fig. 5A, 5B). These prostanoids
are capable of activating TP receptors [17] and may, hence, have
a major contribution to the LPC 20:4-effect (Fig. 4A–C). A recent
study clearly showed that in mouse aorta both exogenously applied
PGI2 (0.03 mM) as well as endogenous, ACh-induced PGI2
potently induced vasoconstriction by acting on TP receptor [32].
In that study, the concentration of 6-keto PGF1a upon ACh-
stimulation was 2 pg/mg tissue, which is 20 times less than what we
observed upon exposure of rings to 20:4 LPC (Fig. 5A).
Figure 3. Blocking of TP receptor improves LPC 18:2- and 20:4-
induced attenuation of relaxation. The rings were preincubated
without (no LPC) or with 10 mM LPC 18:2 (A) or 20:4 (B) in the absence
or presence of 10 mM SQ29548, a TP receptor antagonist for
30 minutes, followed by precontraction with NE and cumulative
addition of ACh. Results are mean 6 SEM of 12 rings from 6 mice.
*P,0.05, **P,0.01***P,0.001.
doi:10.1371/journal.pone.0065155.g003
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Accordingly, 40 pg/mg of 6-keto PGF1a in 20:4 LPC-treated rings
strongly argues for a PGI2-induced vasoconstriction via TP
receptors in our experimental model. Additionally, the decreased
ability of IP receptors to promote relaxation, as found in vascular
smooth muscles of SHR [30], and/or markedly higher levels of TP
compared with IP receptors in mouse aortic smooth muscle cells
[31], might facilitate vasoconstriction in 20:4 LPC-treated rings,
despite increased PGI2 production. Future experiments should
reveal whether responsiveness of IP receptors to PGI2 or its stable
analogue, iloprost, is altered by LPC.
Neither TXA2 nor PGI2 were involved in LPC 18:2-induced
relaxation attenuation (Fig. S3A, S3B). However, the robust
counteracting effect of the TP receptor antagonist on the LPC
18:2-induced relaxation attenuation (Fig. 3A) strongly suggests the
existence and action of some LPC 18:2-induced TP-receptor
agonists. Because LPC 18:2 induced PGF2a (Fig. 5D) which can
Figure 4. Inhibition of TXA2- and PGI2- synthase improves relaxation attenuated by LPC 20:4. The rings were preincubated without (no
LPC) or with LPC 20:4 in the absence or presence of 10 mM furegrelate, a TXA2 synthase inhibitor (A) or 10 mM tranylcypromine, a PGI2 synthase
inhibitor (B) or a combination of both (C) for 30 minutes, followed by precontraction with NE and cumulative addition of ACh. Results are mean 6
SEM of 12 rings from 6 mice. *P,0.05, **P,0.01.
doi:10.1371/journal.pone.0065155.g004
Lysophosphatidylcholine and Vasorelaxation
PLOS ONE | www.plosone.org 6 May 2013 | Volume 8 | Issue 5 | e65155
activate TP receptors [17], the LPC 18:2-induced attenuation of
relaxation might at least in part be due to the EDCF-activity of
induced PGF2a. Furthermore, isoprostanes such as 8-epi-PGF2a
formed non-enzymatically by ROS induced peroxidation of cell
membrane polyunsaturated fatty acids, as well as PGH2, a direct
product of COX, might by acting via TP receptors, contribute to
observed attenuating effect of LPC 18:2 on relaxation. Likewise,
PGE2 and PGF2a [24] both markedly increased with LPC 20:4
(Fig. 5C, 5D) might contribute by acting via the TP receptors, to
the relaxation attenuation induced by LPC 20:4. Due to the
negligible expression of PGE2 receptors EP1 and EP3 (receptors
associated with contraction) in mouse aortic smooth muscle cells,
their contribution to contraction seems unlikely [27].
Previous studies found contradictory effects of LPC 16:0 on
vasorelaxation, most probably attributable to vascular bed- and
species- specific differences in tissue responsiveness to LPC [33–
36]. In our experimental system LPC 16:0 increased the nitrite
levels (indicative of NO levels) in organ bath of aortic rings
exposed to ACh (Fig. S5), arguing against decreased NO as a cause
of relaxation impairment induced by this LPC. Importantly, SNP-
induced relaxation was not altered by the presence of LPC 16:0,
indicating that responsiveness of smooth muscle cells to NO was
not impaired by this LPC (Fig. S1A).
We found that in contrast to the tested unsaturated LPC species,
the rate of ACh-induced relaxation in the presence of LPC 16:0 is
the sum of 16:0-LPC-induced attenuation of relaxation (by a so far
unknown mechanism) and promotion of relaxation by 16:0-LPC-
induced PGI2 (Figs. 2B and 5A). By contrast, a similar induction of
PGI2 by LPC 18:2 (Fig. 5A) failed to promote relaxation. This
difference between LPC 16:0 and 18:2 is not clear, but one can
speculate it might be due to the fact that PGI2 is the only
prostanoid upregulated by LPC 16:0, whereas the action of LPC
18:2-induced PGI2 might be disturbed by concomitantly upregu-
lated PGF2a or by detrimental effect of LPC 18:2 on IP receptor
functionality.
Considering the short exposure of aortic rings to LPC (45 min)
in our experiments, the observed augmenting effect of LPC 16:0
on prostanoid production may not reflect upregulation of
Figure 5. Prostanoid release from LPC-treated aortic rings. The rings were incubated in 200 ml aerated PSS under cell culture conditions at
37uC for 1 h. Thereafter, buffer was replaced with fresh PSS supplemented with PSS (control) or 10 mM LPC followed by further incubation under cell
culture conditions at 37uC for 1 h. (A) 6-keto PGF1a, a stable degradation product of PGI2 (B), TXB2, a stable degradation product of TXA2, (C) PGE2 and
(D) PGF2a were quantified by EIA assays and rings were solubilized for protein quantification. Results shown in A and B are means 6 SD of four
experiments and those in C and D of three experiments, done in triplicates. *P,0.05, **P,0.01***P,0.001.
doi:10.1371/journal.pone.0065155.g005
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PLOS ONE | www.plosone.org 7 May 2013 | Volume 8 | Issue 5 | e65155
underlying enzymes such as COX-2 or respective prostanoid
synthases. Indeed, in our recent study, the LPC-induced COX-2
protein upregulation in endothelial cells was detectable not earlier
than after 3 h of incubation with LPC [37]. Hence, in line with our
previous findings [21] the observed increase in prostanoid
production upon exposure of aortic rings to LPC is rather a
consequence of an acute effect of LPC, namely LPC-induced
increase in cytosolic calcium concentration with concomitant
activation of phospholipase-mediated release of arachidonic acid
from membrane phospholipids. Because in contrast to LPC 16:0,
18:1 and 18:2, LPC 20:4 not only induces arachidonic acid release,
but also provides its own arachidonic acid to COX [21], 20:4 LPC
elicited the highest prostanoid production in aortic rings (Fig. 5A).
Besides vasoconstricting prostanoids, ROS are established
EDCF [17]. In contrast to LPC 18:1, 18:2 and 20:4, LPC 16:0-
induced attenuation of relaxation could not be improved by
tempol, a SOD mimetic [26] (Fig. 6). Similarly, LPC 16:0
promoted ROS production in rat aortic rings, but MnCl2, another
SOD mimetic, failed to restore the impaired relaxation [36]. As
found for tempol, a combination of 10 mM DETCA (SOD
inhibitor) and 100 mM TIRON (ROS scavenger) failed to improve
relaxation attenuated by LPC 16:0 (Fig. S6). The most prominent
tempol-mediated improvement of relaxation was observed with
LPC 18:1, most likely due to the fact that only increased ROS and
not concomitantly increased vasoconstricting prostanoids underlie
the LPC 18:1-induced relaxation attenuation.
Since LPC used in the present study were prepared by PLA2-
mediated cleavage of di-16:0-, -18:1-, -18:2- and -20:4-PC [6],
applied LPCs are sn-1-acyl sn-2-lyso LPC. This is in a good
accordance with situation in vivo where sn-1-lyso sn-2 –acyl LPC
generated by sn-1 phospholipases (such as EL or HL) give rise to
sn-1-acyl isomers due to a rapid migration of acyl chains (in
aqueous medium at neutral pH at 37uC) from the sn-2 to the
deacylated sn-1 position to give a more stable intermediate [38].
Whether sn-1 and sn-2 LPC isomers differ in their biological
activities regarding modulation of endothelial function and
vascular reactivity remains to be determined.
Based on our results, LPC 16:0, 18:1, 18:2 and 20:4 emerge as
important triggers of endothelial dysfunction. The major players
responsible for the blunted endothelium-dependent relaxation in
aged vessels and in various pathologies (essential hypertension,
diabetes and atherosclerosis) are vasoconstricting prostanoids and
ROS [17,28]. The fact that the studied LPC promote the
production of these established EDCF strongly argues for the role
of LPC 16:0, 18:1, 18:2 and 20:4 as important contributors to
endothelial dysfunction in aging and aforementioned pathologies.
Future experiments should reveal the relationship between
plasma levels of those LPC and the incidence and degree of
endothelial dysfunction in humans and animal models of
hypertension.
Supporting Information
Figure S1 SNP-induced relaxation is not affected by
prior exposure of rings to LPC. The rings were preincubated
without (no LPC) or with 10 mM LPC 16:0 (A), 18:1 (B), 18:2 (C)
or 20:4 (D) for 30 minutes, followed by precontraction with NE
and cumulative addition of ACh. Rings were rinsed thoroughly
Figure 6. ROS are induced by LPC and contribute to LPC-induced impairment of relaxation. A) The rings were equilibrated in 100 ml PSS
buffer containing 10 mM DETCA and 10 mM lucigenin at 37uC for 30 minutes, followed by addition of PSS (control) or LPC (10 mM). Emitted light (RLU)
was recorded every 10 seconds for 30 seconds. The RLU were normalised to protein content of respective aortic rings and expressed as percentage
of control set to 100%. Results are means 6 SEM of three separate experiments, each performed with three rings for each LPC. The rings were
preincubated without (no LPC) or with 10 mM LPC 18:1 (B), 18:2 (C), 20:4 (D) or 16:0 (E) in the absence or presence of 200 mM Tempol for 30 minutes,
followed by precontraction with NE and cumulative addition of ACh. Results for each condition are mean 6 SEM of 12 rings from 6 mice. *P,0.05,
**P,0.01.
doi:10.1371/journal.pone.0065155.g006
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with PSS. Thereafter, the rings were precontracted with NE,
followed by cumulative addition of SNP (0.1 nM to 30 nM).
Relaxation values were expressed as a percentage of the NE-
induced contraction. Results of each experimental condition are
mean 6 SEM of 16 rings for each case from 4 mice.
(TIFF)
Figure S2 LPC 18:1-induced attenuation of relaxation is
not affected by indomethacin. The rings were preincubated
without (no LPC) or with 10 mM LPC 18:1 for 30 minutes,
followed by precontraction with NE and cumulative addition of
ACh. Relaxation values were expressed as a percentage of the NE-
induced contraction. Results are mean6 SEM of 12 rings for each
case from 6 mice.
(TIFF)
Figure S3 Furegrelate and tranylcypromine fail to
recover relaxation attenuated by LPC 18:2. The rings were
preincubated without (no LPC) or with LPC 18:2 in the absence or
presence of 10 mM furegrelate (A) or 10 mM tranylcypromine (B)
for 30 minutes, followed by precontraction with NE and
cumulative addition of ACh. Relaxation values were expressed
as a percentage of the NE-induced contraction. Results are mean
6 SEM of 12 rings for each case from 6 mice.
(TIFF)
Figure S4 Inhibition of eNOS by L-NNA but not of COX
by indomethacin abolishes Ach-induced relaxation in
mouse aortic rings. The rings precontracted with NE were
relaxed by a cumulative addition of Ach in the absence (no L-
NNA) or presence of 200 mM L-NNA (A) or 20 mM indomethacin
(B). Relaxation values were expressed as a percentage of the NE-
induced contraction. Results are mean 6 SEM of 8 rings for each
case from 4 mice.
(TIFF)
Figure S5 LPC 16:0 increases nitrite levels released
from aortic rings exposed to Ach. The rings were
precontracted with NE and relaxed by cumulative addition of
Ach. After wash-out of ACh, the same rings were preincubated
with 10 mM LPC 16:0 for 30 min followed by a new contraction-
relaxation cycle. The nitrite levels were determined in incubation
buffers after the first (control) and the second contraction-
relaxation cycle (LPC 16:0). Results are mean 6 SEM of 16 rings
for each case from 4 mice. When LPC was omitted the nitrite
levels released from rings were similar in the first and the second
contraction-relaxation cycle (not shown).
(TIFF)
Figure S6 Combination of DETCA (SOD inhibitor) and
TIRON (superoxide ion scavenger) fail to counteract
LPC 16:0-induced attenuation of relaxation. The rings
were preincubated without (no LPC) or with 10 mM LPC 16:0 in
the absence or presence of DETCA (10 mM) and TIRON
(100 mM) for 30 minutes, followed by precontraction with NE
and cumulative addition of ACh. Results for each condition are
mean 6 SEM of 8 rings from 4 mice.
(TIFF)
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